Latest Product Development News

Eneco Refresh Limited has posted a 6.8% increase in revenue to $17.73 million for FY2026, alongside a remarkable 2072% jump in comprehensive profit after tax to $446,000, driven by operational improvements and resilience amid market volatility.

Clever Culture Systems expanded its pharmaceutical customer base to eight in FY26, placing 11 APAS Independence instruments and completing its product offering with a contact plate module. Despite a $2.24 million net loss, the company expects meaningful sales growth in FY27 backed by a robust pipeline and disciplined financial management.

Orbital Corporation has broadened its customer base and product lineup, positioning itself to capture growth in defence and commercial UAV markets with $3.2 million in expected sales for Q1 FY2027.

Hydrix is ramping up its defence technology efforts, focusing on sensing and autonomous systems aligned with Australia’s $425 billion 2026 National Defence Strategy. The company is developing internal prototypes and forging partnerships to commercialise intellectual property in counter-drone and ISR applications.

IODM Limited’s FY26 results show solid revenue gains led by UK education, but losses persist with a net deficiency in equity raising going concern questions.

xReality Group (ASX: XRG) delivered a standout FY26 with total income up 43% to $20 million and EBITDA surging to $3.8 million, backed by rapid expansion of its Operator XR defence training platform.

Praemium Limited reported a 5.7% revenue increase to $110.5 million and a 21.1% jump in funds under administration to $77.9 billion for FY26, driven by strong high-net-worth segment growth and the integration of OneVue. The acquisition of Technotia Laboratories and a major technology restructure signal a sharpened focus on innovation and cost efficiency.

Singular Health Group lifted revenues over fivefold to $1.43 million in FY26, driven by US commercial rollouts of its 3DICOM platform, but posted a $6.34 million loss. The company strengthened its US foothold with FDA clearance and a controlling stake in an associate.

OMG Group posted a 48% revenue increase to $6.13 million in FY26, achieving its highest-ever gross margin of 41% while expanding distribution into New Zealand and Southeast Asia.

Papyrus Australia has expanded its TBS contract for an additional sample run after mixed trial results and secured a $200,000 unsecured loan with Irwin Biotech, advancing its capital raising efforts with L39 Capital.

Boresight Ltd (ASX: BST) recorded a 46% increase in revenue to $6.38 million for FY26, driven by global sales expansion and strategic investments including an $8 million IPO. Despite this growth, the company posted a $6.66 million net loss, largely due to increased operational expenses and significant share-based payments.

Bio-Gene Technology narrowed its loss to $2.33 million in FY26 while progressing key toxicity studies for Flavocide and securing a commercial foothold for Qcide in Japan. The company bolstered its balance sheet with a $3.275 million capital raise to fund ongoing development and production scale-up.